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Osteoclast enlargement in endstage renal disease. In normal subjects
and patients with endstage renal disease, osteoclast cell volumes were
constructed using serial 2-sm thick plastic embedded sections from iliac
crest bone biopsy specimens. Four cells randomly selected from each of
the subjects were analyzed to give both the cell volume from the
cumulative areas and thickness of each cell slice and also the cell axes
taking the vector along the bone face as width or Y, thickness from the
bone surface as breadth or X and vertical dimension length or Z. The
mean cell volume was 6,230 m3 in the control subjects and was
significantly larger being 11,730 zm3 and 13,680 m3 in the two patient
groups. The cells showed polarity with the largest axes, Y and Z, being
those in apposition to the bone surface, Howship's lacunae were
enlarged in the patients and the cross-sectional area of an individual
lacuna corresponded to the area of the contiguous osteoclast, r = 0.62,P < 0.001. All patients had secondary hyperparathyroidism and
osteoclast numbers were increased. There was no correlation between
osteoclast size and duration of renal failure, previous vitamin D intake,
or aluminum exposure. It is suggested that in ESRD, osteoclasts
undergo both an increase in number and size and that these cells, being
larger, remove more bone than the smaller cells in normal subjects.
Grossissement osteoclastique dans l'insulllsance rénale terminale. Chez
des sujets normaux et des malades en insuffisance rénale terminale, les
volumes cellulaires des ostéoclastes ont été construits en utilisant les
sections sriées de 2-sm d'epaisseur provenant de specimens
biopsiques de crete iliaque incluses dans du plastique. Quatre cellules
de chacun des sujets, sélectionnées au hasard, étaient analysees pour
obtenir Ic volume cellulaire a. partir des surfaces cumulatives et de
l'epaisseur de chaque coupe cellulaire, ainsi que les axes cellulaires en
prenant le vecteur le long de la face osseuse comme largeur ou Y,
l'épaisseur a. partir de Ia surface osseuse comme longueur ou X et Ia
hauteur verticale ou Z. Le volume cellulaire moyen était de 6 230 m3
chez les contrôles et était significativement plus grand, de 11 730 sm3 et
13 680 m3 dans les deux groupes de malades. Les cellules montraient
une polarité, les axes les plus longs (Y et Z) étant ceux en apposition a.
Ia surface osseuse. Les lacunes de Howship étaient élargies chez les
malacles et Ia surface de section transversale d'une lacune individuelle
correspondait ala surface de l'ostéoclaste contigu, r = 0,62, P < 0,001.
Tous les malades avaient une hyperparathyroidie secondaire et leur
nombre d'ostéoclastes était accru. Ii n'y avait pas de correlation entre
Ia taille osteoclastique et la durëe d'insuffisance rénale, l'apport de
vitamine D, ou l'exposition a. l'aluminium antérieurs. 11 est suggéré
qu'en ESRD les ostéoclastes subissent une augmentation de nombre et
de taille, et que ces cellules, devenant plus grosses, enlèvent plus d'os
que les cellules plus petites de sujets normaux.
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Among the variety of abnormalities in bone histology found
in endstage renal disease (ESRD) there is usually an increase in
the number of osteoclasts. These cells are involved in bone
removal. Previous work suggests that the amount of bone each
osteoclast removes is reduced in chronic renal failure [1—3].
Information about the size of the cells, their orientation to the
surface of the trabeculum, and the size of the contiguous
Howship's lacunae, could provide useful information about
whether these cells differ in any respect from those in healthy
subjects.
It has been shown that osteoclast nuclei (and presumably cell
size) were increased in number in Paget disease, associated
with excessive bone turnover [4]. In some patients with
osteopetrosis however, abnormally large osteoclasts are com-
bined with defective function and low rates of bone removal [5].
We are unaware of any other detailed study of osteoclast size in
patients with metabolic bone disease, however, osteoclast
enlargement was found in tibiae of either calcium or phosphorus
deficient rats associated with increased rates of bone resorp-
tion, and the morphological variability of these cells in normal
animals has been repeatedly noted 16—8].
The aim of the present study was to see whether osteoclasts
were altered in size in ESRD and to attempt an approximation
of the quantity of bone each cell removed.
Methods
Biopsy specimens were taken for diagnostic purposes from
the anterior iliac crest using a trephine [9]. All 28 patients
studied had ESRD and were either biopsied a few months
before commencing dialysis or after they had been on dialysis
for more than 1 year. The primary diagnosis was chronic
glomerular disease in eight, polycystic kidneys in six, nephro-
sclerosis in three, obstructive uropathy in two, and one with
hereditary nephritis. In eight the diagnosis was unknown. The
patients from Le Centre Hospitalier COte des Neiges were
biopsied mainly to assess aluminum storage; other biopsy
specimens aided in evaluation of osteodystrophy either for
severity or for baseline data. There were 11 normal control
subjects, eight of whom had bone removed under general
anesthesia for grafting. Five of these were for orthopedic
procedures for non-united fractures, and three were mandibular
osteotomies. All were ambulatory and otherwise in good health.
Three volunteers were biopsied under local anesthesia.
574
M
M
F
M
M
M
F
F
F
F
M
Osteoclast enlargement in endstage renal disease 575
Table 1. Clinical data°
Biopsy specimens were fixed in 1:1 10% buffered formalin
phosphate and 0.5% sucrose solution for 2 hr. They were then
dehydrated in propanol and embedded in glycol methacrylate
[10, 11]. The entire procedure was carried out at 4°C. Serial
2-gm thick sections (125, patients, and 250, control subjects)
were cut using a microtome (Porter-Blum MT2, Dupont Instru-
ments, Sorvall Operations, Newton, Connecticut, USA) and
glass knives. Sections were stained for acid phosphatase and
counterstained with a modified Harris hematoxylin [12, 13].
Mineralized bone stains purple, osteoid light pink, and
osteoclasts bright red. From a section midway through the
series the first acid phosphatase positive area encountered
contiguous to the bone margin was followed in both directions
through the serial sections. If the complete cell could be
identified and if it contained more than a single nucleus
(multinucleate), then it was used for analysis. Using the same
initial section the next area was likewise studied until four cells
had been accumulated for each patient. If there were no further
suitable cells on the initial slide, the search was resumed on a
new section at least 50 m away. The cell and nuclear outlines
were traced using a projection system; the area was measured
using a cursor and the Zeiss system (Zeiss MOP-3). The cell
volume was given by the sum of the areas after correcting each for
the magnification factor of 1740, multiplied by the section thickness.
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Abbreviations: Ca, calcium; P, phosphorus; Alk Phos, alkaline phosphatase; BUN, blood urea nitrogen; Cr, creatinine; PTH x N, number of
times above upper level of normal; X-ray: N = normal, H = hyperparathyroidism, D = demineralization; D Rx, treatment with vitamin D; Al
intake, as phosphate binders; Dialysis type: HH = hospital hemodialysis, HUH = home hemodialysis, IPD = hospital intermittent peritoneal
dialysis, CAPD = continuous ambulatory peritoneal dialysis; Dial, dialysis; Hospitals: MGH = Montreal General Hospital, RVH = Royal Victoria
Hospital, CHCN = Le Centre Hospitalier Côte de Neiges.
a Normal values are: Ca 8.5 to 10.5 mg/dl; P 2.5 to 4.5 mg/dl; Alk Phos 30 to 105 U; BUN 10 to 20 mg/dl; Cr 0.8 to 1.5 mg/dl.
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Fig. 1. Volume of each osteoclast (inverted triangles) for each subject.
error by the horizontal lines.
Each individual cell was orientated by its position relative to
the bone face; this was called the width or Y axis. Cell thickness
from the bone surface was breadth or X axis, and the vertical
dimension of the cell, given by the number of 2 p.m sections,
was the length or Z axis.
Howship lacunar areas were measured in two separate ways.
In the first, every lacunar area which contained a single
osteoclast was measured as the area of bone eroded by that cell.
Every osteoclast-fihled lacuna was measured on the section for
each patient, making a total of 1154 lacunae measured. For each
subject the number of measured Iacunae varied from 5 to 80
with a median of 27 and mean of 30. Sites with multiple cells,
those that were not clearly defined or were intra-trabecular,
were excluded. In the second study the midpoint length of each
of the four osteoclasts used to measure cell volume was used,
and the lacunar area corresponding to the osteoclast area in the
middle of the cell was determined. These data are shown in
Table 2 and graphically in Figure 2. In the first method the
osteoclast and lacunar profiles are random whereas in the
second they are sited at the midpoint length of the cell. Different
sections were used for the two sets of data.
The three-dimensional displays were synthesised from the
manually traced cell contours from a single cell in the control
and before dialysis groups with a volume close to the mean of
each group. These were entered into a Digital Equipment
The mean for the four cells is given by the vertical bar and the standard
Corporation VAX 11/780 using a Summagraphics Corporation
Bitpad-One digitizing tablet. Fifty points per contour were
evenly distributed according to distance. Then the digitized
contours were triangulated using a minimum connecting line
distance algorithm implemented in the MOSAIC program of the
MOVIE.BYU package. The three-dimensional wire frame rep-
resentation was rendered onto a Tektronix 4050 storage tube
display using the MOVIE.BYU display package [141. As in-
dicated, the tracing of the adjacent bone face was used as a
point of reference for cell orientation, Figure 3. Cell length, axis
Z, was measured from the number of sections through which
each of the four osteoclasts per patient extended. Y or width
along the bone face and X, or breadth, were obtained from the
projected cell tracing using the mean of measurements taken at
25, 50, and 75% along the Z axis to provide a representative
value. The data in Table 2 under width, breadth, and length
represent the mean values of the four cells studied in each
patient.
Parathyroid hormone (PTH) levels using a C terminal specific
antiserum were measured at the Montreal General Hospital and
one sensitive to both amino and carboxy terminals at the Royal
Victoria Hospital. For uniformity the results are expressed as
multiples of the upper normal limit. A single assay using a
middle molecule antisera was also carried out at the Montreal
General Hospital. Aluminum staining was done on 8-p.m thick
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sections without counterstain as described previously [15].
Correlation between aluminum surface of trabecular bone and
analyzed cortical aluminum content from the same biopsy
specimen was 0.78, P < 0.001 for 44 samples. Morphometric
measurements for resorption areas, osteoid and aluminum,
were made with the projection system, tracing the total bone
surface and then quantitating with the cursor. Analyses were
confined to trabecular bone. The Student t test was used for
comparison between means. Because of the wide range in
osteoclast volume in the same individual, it was considered
statistically valid to treat each cell as a separate unit. Differ-
ences between groups were unchanged and for uniformity the
mean value for each individual has been given in Table 1 with
the variation shown graphically in Figure 1.
Results
The clinical and biochemical data for the patients is shown in
Table 1. While all subjects had renal failure there was hetero-
geneity in the severity of bone disease, vitamin D treatment,
aluminum exposure, and duration and type of dialysis. Mean
values for calcium and creatinine were lower (P < 0.001 and <
0.05) in the group before starting dialysis, otherwise the mea-
sured parameters showed no significant differences between the
two ESRD groups. Only one patient received D treatment
before dialysis whereas more than one-half did on dialysis. One
of the patients received dihydrotachysterol and the remainder
1,25 dihydroxycholecalciferol. Most patients were not exposed
to aluminum containing phosphate binders prior to dialysis
while the majority were exposed while on dialysis.
Osteoclast parameters were distributed randomly in the con-
trol subjects, and no difference was present whether the sam-
ples were obtained under local (patients 9 to 11) or general
anesthesia. Osteoclast numbers and volume increased in both
renal failure groups. The numbers shown for cell volume in
Table 1 are the mean of the four cells measured for each
subject. The data for each individual cell are shown in Figure 1.
There is considerable variation in cell size within each indi-
vidual, particularly in the ESRD patients. Means of both ESRD
groups are significantly different from the control mean but are
not different from each other. Nuclear volume increased in a
similar manner to cell volume so that the cell/nuclei volume
ratio remained constant.
Accompanying the increase in osteoclast size, the Howship
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Fig. 2. Comparison of midsection osteoclast area and corresponding lacunar area. All cells have been plotted but there were no lacunae in 21%
of the control subjects and 16% of the ESRD patients. The insert shows enlargement of the area up to 600 tm2 which includes 80% of all the values.
For control subjects r = 0.87, P < 0.001, y = —0.72 + l.03x, while for all groups r = 0.62, P < 0.001, and y = —0.37 + 0.9x. Symbols are:
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Table 2. Morphometric data
lacunae measured in the first study for all profiles were 1.7
0.linthecontrolgroupand4.6 0.6and4.8 0.4zm2 x 102
in the two patient groups; P < 0.001 as compared with the
control group. In the second study the lacunar area was
proportional to the area of the contiguous osteoclast when
measured at the midpoint on each of four cells per patient. This
relationship was closest for the controls, r = 0.87, while for all
groups r = 0.62, P < 0.001, Figure 2 and Table 2. Mean cross
sectional and lacunar areas did not differ from the control
values.
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For the osteoclast data the values given are the mean of the four cells analyzed for each subject.
a Osteoclasts/mm trabecular surface.
OC—osteoclast.
Ratio of cell to nuclear volume.
d Osteoclast area contiguous to bone.
Area at midpoint of cell.
Lacunar area at midpoint of cell.
Resorption %—Percentage of trabecular surface with resorption areas with or without osteoclasts.
Osteoid %—Percentage of trabecular surface covered by osteoid.
'Al %—Percentage of trabecular surface covered by aluminum positive staining.
i P < 0.05 compared with control subjects.
P < 0.01 compared with control subjects.
'P < 0.001 compared with control subjects.
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A picture of the three-dimensional display of two osteoclasts
is shown in Figure 3. The bone surface and XYZ axes have been
superimposed on the print for orientation. The spikes are
artefacts due to the distance between the sections so that the
length between the separate images are closed by straight lines
rather than curves. The control cell appears densely cross-
hatched and is on the upper and lower right of the figure with
the ESRD cell on the left. In the upper pair of images the bone
edge is on the left of each cell and the cell is being viewed from
the top. In the lower pair the bone is posterior to the print and
the view is on the side of the cell which has been rotated 90° in
both Y and X axes. The two cells are equal in the Z axis but this
particular cell is larger in the Y axis. The means for all three
groups show that the Y axis or width along the bone face was
twice as large as the X axis or cell breadth, P < 0.001. There
were small increments for each of the vectors between the
controls and those with ESRD (Table 2). The product of Y
times Z gives the potential cell surface available for resorption
which is larger in the patients on dialysis than the controls, P <
0.01.
Significant correlations were found between osteoclast size
and number as well as resorptive surface or lacunar area but all
other relationships appeared unimportant (Table 3). Subdivi-
sion of the patients according to whether they were treated with
vitamin D compounds or were exposed to aluminum showed no
significant differences.
Discussion
The study group exemplifies the diversity among patients
with ESRD; this is accentuated by the inclusion of subjects
from different institutions both prior to and following the
commencement of regular dialysis treatment. Notwithstanding
these factors, osteoclast enlargement was found irrespective of
the stage of renal failure, type and duration of renal disease,
presence or absence of previous 1,25 dihydroxycholecalciferol
therapy, or significant aluminum storage. The only two aspects
that were common to all patients were the presence of ESRD
and the accompanying hyperparathyroidism. Several previous
studies have demonstrated significant correlations between
measured serum levels of immunoreactive parathyroid hor-
mone (iPTH) and osteoclast counts, whether these are specifi-
cally identified by the acid phosphatase reaction or not [16—191.
However, the correlation is not as striking as in primary
hyperparathyroidism indicating that in renal failure other fac-
tors such as PTH resistance and heterogeneity of circulating
iPTH lead to greater variation between osteoclast quantitation
and iPTH levels [2 1—231. In fact some authors have been unable
to demonstrate any useful relationship between iPTH and
osteoclast counts, particularly when the former was measured
using carboxyl terminal specific assays. Thus, in the study of
Recker et al [24] patients treated with 1,25 hydroxycho-
lecalciferol showed clinical and biochemical improvement with
falls in osteoclast counts but without changes in iPTH. We
interpret our results as showing evidence of marked hyper-
parathyroidism but lacking in discrimination between patients.
Hence the failure to correlate with the osteoclast counts reflects
the limitations of the iPTH assay:
The increase in osteoclast volume in ESRD is due to small
increases in each of the XYZ vectors. The polarity of the cell is
clearly shown by these measurements together with the three-
dimensional display. The major orientation of the cell is to the
bone surface with the breadth or X axis the smallest of the three
vectors.
The status of the osteoclast in ESRD requires consideration.
The enlargement could be due to a normal cell that is increased
in size or alternatively an augmented impotent cell as in some
patients with congenital osteopetrosis [51. In favor of the view
that these cells are normal are the following observations: (1)
The osteoclast enlargement correlates best with osteoclast
numbers; the latter is accepted as a reliable indicator of
hyperparathyroidism, either primary or secondary with in-
creased bone resorption as a characteristic of this condition. (2)
The data showing that the midpoint osteoclast area and hence
cell size is related to lacunar area, indicating that the larger the
cell the more bone it removes. Big osteoclasts remove more
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Table 3. Correlative values
r
Pairs of
obser-
vations P
Osteoclast volume and Osteoclasts/mm
Midsection area
Resorptive surface %
Aluminum mm/mma
PTH middle
molecule
Alkaline phosphatase
PTH C-terminal
0.50
0.36
0.35
0.21
0.09
0.07
0.04
39
39
39
28
17
28
21
<01
<05
<05
NS
NS
NS
NS
Osteoclasts/mm and Resorptive surface %
Alkaline phosphatase
Aluminum mm/mma
PTH C-terminal
Midsection area
PTH middle
molecule
0.89
0.26
—0.18
0.15
0.11
0.02
30
28
28
21
39
17
<001
NS
NS
NS
NS
NS
a Control subjects were excluded because aluminum staining was
never present.
x
Fig. 3. Computer-derived three-dimensional display of a control cell(patient 9) above and below on the right anda cell from a patient before
dialysis (patient 10) on the left. The bone has been indicated by placing
on the print the superimposed diagonal lines and the XYZ axes are also
shown. In the upper two images the view is from the top of the cell and
the last section looking down to the first section, Z axis. The bone edge
is to the left of the cell along the Y axis. In the lower images the bone
is behind the cell in the plane of the paper.
bone than small ones by a factor of almost three to one.
Furthermore, the slope of the regression line relating lacunar
size to midpoint osteoclast area is the same for both control and
ESRD cells. (3) The stability of overall cell size to nuclear size
suggests that the cells' functional status is normal and that they
are not incompetent. Seen in this way, the bone resorbed per
unit of cell, for example per nucleus, remains constant. How-
ever, as there are more units to each cell, more bone is
removed. This occurs both in the normal bone and in those with
ESRD. Reconciliation of our findings and interpretation with
those of Jaworski, Lok, and Wellington [2] and Hitt et al [251
may be possible if the difference in methodology and in subject
material is considered. In the initial study in humans, resorption
rates were determined indirectly in the rib using Frost's tech-
nique. The subjects were severely uremic with depressed bone
formation rates. Likewise, the rat experiments were in acutely
uremic animals and are not comparable to the present subjects
who were in a steady-state chronic condition [3]. The chroni-
cally uremic dogs had very mild hyperparathyroidism incompa-
rable in severity to the patients in this study. While the bone
removed per unit time was less in the animals with impaired
renal function, the number of osteoclasts involved were not
counted [2]. Finally all these studies pertain to compact Haver-
sian bone whereas ours are limited to the endosteal surface of
spongeous bone. It is possible that the two sites differ. In this
respect Jaworski, Lok, and Wellington [2] have commented on
the larger osteoclast erosive areas in normal trabecular as
compared with cortical bone.
We conclude that osteoclasts are increased in both number
and size in iliac crest trabecular bone of ESRD patients. The
data are compatible with the view that these cells which are
larger remove more bone, with the reservation that the findings
cannot be applied indiscriminately to Haversian bone until
further studies have been done.
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